Profile data is unavailable for this security.
About the company
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
- Revenue in CAD (TTM)14.04bn
- Net income in CAD214.71m
- Incorporated2013
- Employees20.30k
- LocationBausch Health Companies Inc2150 St. Elzear Blvd. WestLAVAL H7L 4A8CanadaCAN
- Phone+1 (514) 744-6792
- Fax+1 (514) 744-6792
- Websitehttps://www.bauschhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Perrigo Company PLC | 4.25bn | -1.40bn | 1.70bn | 8.10k | -- | 0.5784 | -- | 0.3994 | -10.19 | -10.36 | 30.80 | 21.33 | 0.4678 | 2.47 | 6.37 | 525,074.10 | -15.42 | -3.52 | -17.39 | -4.03 | 35.14 | 34.70 | -32.97 | -8.36 | 1.63 | 1.91 | 0.5536 | -- | -2.75 | 0.794 | -772.62 | -- | -14.60 | 5.21 |
| Sarepta Therapeutics Inc | 2.20bn | -842.79m | 1.71bn | 1.37k | -- | 1.50 | -- | 0.7793 | -8.44 | -8.44 | 21.50 | 10.87 | 0.6012 | 1.01 | 4.40 | -- | -23.05 | -12.81 | -30.73 | -15.87 | 61.81 | 77.84 | -38.34 | -30.61 | 1.48 | -853.14 | 0.4209 | -- | 15.58 | 32.41 | -403.27 | -- | -- | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.74bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Vericel Corp | 276.26m | 16.52m | 1.79bn | 398.00 | 134.30 | 5.05 | 63.64 | 6.50 | 0.2633 | 0.2633 | 5.26 | 7.01 | 0.6001 | 4.05 | 3.78 | 694,118.10 | 3.59 | -0.0292 | 4.02 | -0.0331 | 74.42 | 70.68 | 5.98 | -0.0467 | 4.68 | -- | 0.0056 | -- | 16.45 | 17.34 | 59.41 | 41.97 | 59.56 | -- |
| Organon & Co | 6.22bn | 187.00m | 1.87bn | 10.00k | 10.03 | 2.49 | 3.42 | 0.3011 | 0.7166 | 0.7166 | 23.86 | 2.89 | 0.4787 | 2.13 | 4.62 | 621,600.00 | 1.44 | 7.45 | 1.79 | 9.65 | 53.30 | 59.42 | 3.01 | 13.85 | 1.23 | 2.62 | 0.92 | 25.68 | -2.92 | -0.9868 | -78.36 | -39.23 | 4.38 | -- |
| Aurinia Pharmaceuticals Inc | 283.06m | 287.20m | 1.89bn | 300.00 | 6.83 | 3.23 | 6.16 | 6.68 | 2.08 | 2.08 | 2.04 | 4.39 | 0.4347 | 0.7693 | 7.26 | -- | 44.11 | -2.73 | 51.71 | -3.10 | 88.46 | 90.63 | 101.47 | -8.50 | 4.76 | -- | 0.1059 | -- | 20.38 | 41.38 | 4,893.08 | -- | -49.05 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.98bn | 382.00 | -- | 42.21 | 145.07 | 7.94 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| Bausch Health Companies Inc | 10.27bn | 157.00m | 2.21bn | 20.30k | 14.33 | -- | 1.66 | 0.2149 | 0.4152 | 0.4152 | 27.56 | -1.50 | 0.3882 | 1.87 | 4.57 | 505,714.30 | 0.4538 | -1.24 | 0.599 | -1.57 | 70.65 | 71.00 | 1.17 | -3.79 | 1.08 | 1.36 | 0.9822 | -- | 6.66 | 5.04 | 441.30 | -- | 5.66 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.21bn | 2.48k | 24.18 | 6.64 | 15.48 | 1.51 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Ultragenyx Pharmaceutical Inc | 673.00m | -575.00m | 2.22bn | 1.37k | -- | -- | -- | 3.31 | -5.83 | -5.83 | 6.83 | -0.8282 | 0.4434 | 2.25 | 4.81 | 490,882.60 | -37.89 | -37.78 | -50.15 | -45.91 | 83.80 | 88.44 | -85.44 | -122.25 | 2.34 | -14.66 | 1.07 | -- | 20.13 | 19.95 | -1.02 | -- | -13.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 2.39bn | 325.00 | -- | 3.62 | -- | 46.01 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Apellis Pharmaceuticals Inc | 1.00bn | 22.39m | 2.65bn | 733.00 | 167.64 | 7.08 | 110.50 | 2.64 | 0.1235 | 0.1235 | 7.90 | 2.92 | 1.02 | 0.913 | 3.18 | 1,369,416.00 | 2.28 | -48.52 | 3.09 | -62.30 | 89.81 | 87.55 | 2.23 | -90.49 | 2.70 | 1.78 | 0.5516 | -- | 28.46 | 31.98 | 111.31 | -- | -43.47 | -- |
| Liquidia Corp | 69.22m | -121.85m | 2.69bn | 157.00 | -- | 121.81 | -- | 38.89 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
Data as of Mar 03 2026. Currency figures normalised to Bausch Health Companies Inc's reporting currency: US Dollar USD
45.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Paulson & Co., Inc.as of 31 Dec 2025 | 73.26m | 19.77% |
| GoldenTree Asset Management LPas of 31 Dec 2025 | 34.67m | 9.36% |
| Nomura Securities Co., Ltd. (Private Banking)as of 30 Sep 2025 | 15.71m | 4.24% |
| Nomura Global Financial Products, Inc.as of 31 Dec 2025 | 8.70m | 2.35% |
| Healthcare of Ontario Pension Planas of 31 Dec 2025 | 8.45m | 2.28% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.33m | 1.98% |
| MFN Partners Management LPas of 31 Dec 2025 | 6.00m | 1.62% |
| National Bank Financial, Inc.as of 31 Dec 2025 | 5.26m | 1.42% |
| KKR Investment Management LLCas of 31 Dec 2025 | 5.24m | 1.41% |
| Brewin Dolphin Ltd.as of 31 Dec 2025 | 5.20m | 1.40% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
